Drug Approved for Parkinson’s & RLS

Share on FacebookTweet about this on TwitterShare on LinkedIn

The FDA has approved the rotigotine transdermal system (Neupro, UCB) for signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and for treating moderate-to-severe primary restless legs syndrome, or RLS. The drug was previously approved for early stage idiopathic PD.

Abstract: UCB.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × one =